Meridian Bioscience

Meridian Bioscience Working Capital

The Working Capital of Meridian Bioscience (VIVO) as of Oct 1, 2026 is 152.65 M USD. In the previous year, Working Capital was 145.65 M USD — a change of 4.80% (higher).

Working Capital

152.65 MUSD

YoY

4.80%

Last updated:

Working Capital of Meridian Bioscience is 2026 152.65 M USD. Working Capital of Meridian Bioscience was 2025 145.65 M USD. It decreases by 4.80% higher compared to the previous year.
Access this data via the Eulerpool API

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Working Capital of Meridian Bioscience is 152.65 M USD in 2026.

Working Capital of Meridian Bioscience changed from 145.65 M USD to 152.65 M USD, representing a 4.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's Meridian Bioscience historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Meridian Bioscience

All Key Metrics — Meridian Bioscience